EVA Pharma’s roots stretch back over a hundred years.

thumbnail_Pharmacy.jpeg

Pharmacy.jpeg

Our History

Our experienced leadership team keeps us on track.

thumbnail_Find_Out_More_Leaders.png

Find_Out_More_Leaders.png

Meet our Leaders

EVA Pharma’s success is based on its dynamic team, Our people are our power.

thumbnail_1704997569480.jfif

1704997569480.jfif

Life at EVA Pharma

Are you a Journalist or Media Representative and need information about us? Please feel free to get in touch with our PR Team

thumbnail_pexels-kaboompics-com-6335@2x.png

pexels-kaboompics-com-6335@2x.png

Media Contact 

Event

thumbnail_hero-section-ss.jpg

hero-section-ss.jpg

CPHI Worldwide 2025 Frankfurt EVA Pharma is a global healthcare company operating across 70+ countries, dedicated

CPHI Worldwide 2025

thumbnail_EVAxMIS_Ann-01-web-eng (1).png

EVAxMIS_Ann-01-web-eng (1).png

KSA Saudi Made localization Saudization Empowering health research and development

Saudi Made 2025

thumbnail_EVAxCPHIAHEXCAQ12026_websitebanner 2.png

EVAxCPHIAHEXCAQ12026_websitebanner 2.png

Africa Health ExCon 2026 EVA Pharma is a global healthcare company operating across 40+ countries, dedicated

Africa Health ExCon 2026

thumbnail_EVAxCPHICHINAQ12026_websitebanner 3.png

EVAxCPHICHINAQ12026_websitebanner 3.png

CPHI China 2026 EVA Pharma is a global healthcare company operating across 40+ countries,

CPHI China 2026

**Cairo, Egypt – June 19, 2026**— EVA Pharma welcomed a high-level delegation from the German Federal Ministry for Economic Cooperation and Development (BMZ) and the Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) to its integrated manufacturing complex in 6th of October City. 

The visit took place on the sidelines of the Global Private Sector Engagement Forum (PSEF), organised by World Health Organization (WHO) through its Product Policies, Access and Manufacturing Support (PAM) Unit and co-convened with the Directorate-General for International Partnerships (DG INTPA) of the European Commission under the Global Gateway framework, and funded by the BMZ. 


The delegation included Ms. Birgit Pickel, Director General for Sustainable Development and Climate at BMZ and Dr. Anna Lotte Böttcher, Senior Policy Officer for Global Health Policy and Financing at BMZ.
The visit highlighted EVA Pharma’s role as a strategic African hub for advancing local pharmaceutical manufacturing, technology transfer from global companies, and sustainable access of life-saving medicines. Moreover, it reflected the shared priorities between African countries and international development partners, aiming to strengthening health systems and long-term health security.

During the visit, the delegation toured EVA Pharma’s advanced production facilities and was briefed on the company’s fully integrated end-to-end manufacturing capabilities. The delegation toured the whole complex with a focus on the sterile manufacturing facility which stands as a testament to the company’s ongoing mission to expand access to lenacapavir across Africa and 120 countries worldwide with high HIV incidence and limited resources, reinforcing its commitment to improving equitable access to innovative HIV treatments, as announced in 2024.


Moreover, the delegation visited EVA Pharma’s mRNA Innovation Hub, a key pillar of the company’s long-term commitment to next-generation vaccine development in Africa. Since becoming operational in January, 2025, the platform has been advancing toward a fully integrated mRNA manufacturing capability, with a planned annual capacity of up to 100 million vials. 
This initiative contributes to continental efforts to expand local vaccine production, supporting Africa CDC’s target of manufacturing 60% of vaccines locally by 2040, while strengthening pandemic preparedness and accelerating technology transfer across the region.

Discussions also explored the critical role of localized manufacturing in building resilient health systems, creating skilled employment opportunities, and supporting sustainable economic development across Africa.
“We are honored to welcome the BMZ and GIZ delegation to our manufacturing facilities,  and we believe that healthcare sovereignty in Africa begins with building strong local capabilities, supported by global collaborations” said Bishoy Faltas, Sub-Sahara Africa Commercial Manager at EVA Pharma. “We continue to expand our footprint in  equitable access to high-quality healthcare solutions as well as life saving medicines to African patients.”


**About EVA Pharma**

EVA Pharma is dedicated to improving access to affordable, high-quality medicines around the world, focusing on three core pillars: innovation, development and sustainable access. The company leverages cutting-edge technology at two research centers bringing first-of-its-kind capabilities to the Middle East and Africa including mRNA research and development from AI prediction to biological products.  
With a 5,000-strong team of professionals, EVA Pharma produces more than one million healthcare products a day at four state-of-the-art manufacturing facilities, which are internationally recognized for innovation, and have been approved by multiple regulatory agencies.  
Guided by a relentless drive to ensure sustainable access to pressing yet unmet disease areas, the company’s product portfolio focuses on twelve therapeutic areas: Anti-infectives, metabolic health, bone, neuroscience, oncology, respiratory, gynecology, urology and andrology, pediatrics, ophthalmology, gastrointestinal tract, family medicine to meet both local and international demand.  
EVA Pharma is one of the fastest-growing healthcare companies in the Middle East and Africa, with an extensive pan-African presence, while operating in more than 40 countries worldwide.  
 




thumbnail_Group Photo (2).jpeg

Group Photo (2).jpeg

Press Release

EVA Pharma is dedicated to improving access to affordable, high-quality medicines around the world, focusing on three core pillars.

EVA Pharma Hosts a High-Level Delegation from Germany’s Federal Ministry for Economic Cooperation and Development (BMZ) and Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ)

Cairo, Egypt- 4 November 2025-&nbsp;EVA Pharma launched a specialized oncology sector, the press conference was attended by His Excellency Professor Dr. Khaled Abdel Ghaffar, Deputy Prime Minister and Minister of Health and Population; Dr. Ali Al-Ghamrawi, Head of the Egyptian Drug Authority (EDA); Dr. Ahmed Al-Sobky, Head of the Healthcare Authority; Dr. Hossam Abdel Ghaffar, Assistant Minister of Health and Population and the Ministry's Official Spokesperson; and a number of experts and specialists.
&nbsp;
EVA Pharma oncology will work on producing immunotherapy hematology and oncology treatments with an annual production capacity nearing 22 million packs annually. This will be achieved by introducing 7 products into the Egyptian market and for export, with plans to introduce 11 new treatments in the upcoming period.
Dr. Riad Armanious, CEO of EVA Pharma, stated that the launch represents a new national milestone in the company's journey and embodies its commitment to supporting the Egypt’s 2030 vision for healthcare system and expanding access to advanced treatments for oncology patients in Egypt and the MENA region.
Dr. Riad Armanious extended his sincere thanks and appreciation to the Ministry of Health and Population, the Egyptian Drug Authority, and the Healthcare Authority for their continuous support and tremendous efforts to develop Egypt's healthcare system. He emphasized that the support from the political leadership and officials from the ministries and health authorities in Egypt is the true driving force behind the national achievements witnessed today in the medical and pharmaceutical sector.
He added, "Cancer remains one of the most difficult challenges a patient and their family face. In this battle, the presence of strong national leadership makes a real difference. And&nbsp; at EVA Pharma, we are proud to be part of this collaborative effort. "
Dr. Riad Armanious affirmed that EVA Pharma considers itself a national partner in achieving the state's health goals. He added, "We work hand in hand with the Ministry of Health and Population, the Egyptian Drug Authority, the Healthcare Authority, and all our partners in the public and private sectors to ensure the sustainability of these efforts and expand their impact. Success in this system is not achieved by a single party alone but is built on cooperation and integration among all."
&nbsp;
He continued, "Over the past seven years, we have invested in developing an integrated oncology sector and have successfully developed 18 specialized products for treating various types of cancer, including breast, lung, colon, and blood cancers. Some of these are currently available in the markets, and others will be launched soon. Through these products, we contribute to treating thousands of patients annually within Egypt."
&nbsp;
He added that these efforts are implemented through the company's advanced manufacturing facility, which holds EU-GMP certification, with an annual production capacity of 22 million packs. He explained that the company's production capacity exceeds the needs of the local market, allowing Egypt to become a regional hub for exporting oncology drugs to Arab, African, and international markets.

thumbnail_IMG_9048[1].JPG

IMG_9048[1].JPG

EVA Pharma launches EVA Pharma Oncology to Support Critical Medicines Sustainable Access

thumbnail_Glargivin-Photo-2 (1).jpg

Glargivin-Photo-2 (1).jpg

Lilly and EVA Pharma announce regulatory approval and release of locally manufactured insulin in Egypt

&nbsp;
Under this royalty-free voluntary licensing agreement EVA Pharma will manufacture and supply Lenacapavir active pharmaceutical ingredient and finished pharmaceutical product.
&nbsp;
CAIRO, October 3, 2024&nbsp;–<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3735678-1&amp;h=1130473503&amp;u=http%3A%2F%2Fwww.evapharma.com%2F&amp;a=EVA+Pharma" target="_blank" rel="noopener"><span style="font-size: 11.0pt; font-family: 'IBM Plex Sans Arabic',sans-serif; mso-fareast-font-family: 'Times New Roman'; color: #007bff; border: none windowtext 1.0pt; mso-border-alt: none windowtext 0in; padding: 0in;">EVA Pharma</a>&nbsp;announced today a non-exclusive, royalty-free voluntary licensing agreement signed with <a href="https://www.gilead.com/news/news-details/2024/gilead-signs-royalty-free-voluntary-licensing-agreements-with-six-generic-manufacturers-to-increase-access-to-lenacapavir-for-hiv-prevention-in-high-incidence-resource-limited-countries">Gilead</a>, allowing EVA Pharma to manufacture and supply generic lenacapavir in form of active pharmaceutical ingredient and finished pharmaceutical product. This agreement includes the technology transfer of know-how to make and use lenacapavir allowing for sustainable accessibility to lenacapavir in 120 high-incidence, resource-limited countries through EVA Pharma’s local manufacturing capabilities and strong foothold in Africa.
&nbsp;
The agreement covers lenacapavir for HIV treatment in heavily treatment-experienced (HTE) adults with multi-drug-resistant HIV, as well as lenacapavir for HIV prevention (pending approval). Gilead is exploring frameworks such as the European Medicines Agency’s EU Medicines for All with the aim of expediting both U.S. FDA procedures and the attainment of WHO prequalification. This will enable EVA Pharma to submit its high-quality generic lenacapavir for multiple regulatory authorities to support demand and broaden accessibility across 120 countries.
&nbsp;
“<a href="https://www.unaids.org/sites/default/files/media_asset/2024-unaids-global-aids-update_en.pdf">The urgency of NOW</a> demands that we go fast and far to end HIV/AIDS. This goal is only reached through collective efforts, from innovation to sustainable access to medicines.” said Riad Armanious, CEO of EVA Pharma. “To this commitment we stand our ground as the sole licensee on Africa, EVA Pharma has already rolled the ball on fast-track actions towards our joint mission with Gilead. Combining Gilead’s expertise and EVA Pharma’s capabilities and reach we ensure that no one is left behind in the fight against HIV.”
&nbsp;
&nbsp;
&nbsp;
“EVA Pharma has been committed to the fight against HIV since 2003, consistently empowering governments and healthcare systems to support patient care across Africa” said Amgad Talaat, Strategic Alliances Director at EVA Pharma. “In our ongoing effort to ensure sustainable access, EVA Pharma has expanded its focus to localizing drug substance production. In collaboration with Gilead we have been setting numerous firsts in the area of generic voluntary licensing, from combatting HCV to making remdesivir available for COVID patients. And now, we embark on another significant milestone by supplying lenacapavir to patients across the continent, including South Africa for the first time” 
&nbsp;
Of the six generic manufacturers in Gilead’s voluntary licensing agreement, EVA Pharma is the sole local manufacturer in Africa. Responding to the urgency of this shared mission, EVA Pharma expects to complete lenacapavir API manufacturing by the end of 2024, following the completion of the tech-transfer from Gilead, paving the way for the production of lenacapavir finished product. The company expects to begin supplying the high-quality, African-made lenacapavir within 25 months. Leveraging its extensive pan-African reach, EVA Pharma will supply the medicine to 120 countries, with the first phase of export including 18 countries representing the highest incidence rate (about 70% of the HIV burden in the countries named in the license) to receive lenacapavir as quickly as possible. These countries are Botswana, Eswatini, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Nigeria, Philippines, Rwanda, South Africa, Tanzania, Thailand, Uganda, Vietnam, Zambia and Zimbabwe. 
&nbsp;
&nbsp;
--end of release--
&nbsp;
&nbsp;
About EVA Pharma
EVA Pharma is dedicated to improving access to affordable, high-quality medicines around the world, focusing on three core pillars: innovation, development and sustainable access. The company leverages cutting-edge technology at two research centers bringing first-of-its-kind capabilities to the Middle East and Africa including mRNA research and development from AI prediction to biologic product.
&nbsp;
With a 5,000-strong team of professionals, EVA Pharma produces more than one million healthcare products a day at four state-of-the-art manufacturing facilities, which are internationally recognized for innovation, and have been approved by multiple regulatory agencies.
&nbsp;
Guided by a relentless drive to ensure sustainable access to pressing, yet unmet, disease areas, the company’s product portfolio focuses on twelve therapeutic areas: Anti-infectives, metabolic health, bone, neuroscience, oncology, respiratory, gynecology, urology and andrology, pediatrics, ophthalmology, gastrointestinal tract, family medicine to meet both local and international demand.
&nbsp;
EVA Pharma is one of the fastest-growing healthcare companies in the Middle East and Africa, with an extensive pan-African presence, while operating in more than 70 countries worldwide.
For more information, please visit: <a href="http://www.evapharma.com/">www.evapharma.com</a> &amp; <a href="https://www.evapharma.com/newsroom">https://www.evapharma.com/newsroom</a> or follow us on <a href="https://www.facebook.com/Evapharma/" target="_blank" rel="noopener">Facebook</a>, <a href="https://www.linkedin.com/company/eva-pharma/" target="_blank" rel="noopener">LinkedIn</a> &amp; <a href="https://www.instagram.com/eva.pharma/" target="_blank" rel="noopener">Instagram</a> &nbsp;
&nbsp;
&nbsp;
About Gilead Sciences:
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
&nbsp;
&nbsp;
About Lenacapavir
Lenacapavir is approved in multiple countries for the treatment of adults with multi-drug-resistant HIV in combination with other antiretrovirals. The use of lenacapavir for HIV prevention is investigational and the safety and efficacy of lenacapavir for this use have not been established.
The multi-stage mechanism of action of lenacapavir is distinguishable from other currently approved classes of antiviral agents. While most antivirals act on just one stage of viral replication, lenacapavir is designed to inhibit HIV at multiple stages of its lifecycle and has no known cross resistance exhibited in vitro to other existing drug classes.
Lenacapavir is being evaluated as a long-acting option in multiple ongoing and planned early and late-stage clinical studies in Gilead's HIV prevention and treatment research program. Lenacapavir is being developed as a foundation for potential future HIV therapies with the goal of offering both long-acting oral and injectable options with several dosing frequencies, in combination or as a mono agent, that help address individual needs and preferences of people and communities affected by HIV.

thumbnail_Eva-announcment-10-gilead-for-web 1.png

Eva-announcment-10-gilead-for-web 1.png

EVA Pharma Signs a Voluntary Licensing Agreement with Gilead to Increase Access to Lenacapavir in 120 Countries with High HIV Incidence and Limited Resources

Cairo, Egypt – February 5, 2025 –Africa’s EVA Pharma, France’s DNA Script, and Belgium’s Quantoom Biosciences have signed a Memorandum of Understanding today, on the sidelines of the 2nd Vaccine and Other Health Products Manufacturing Forum for African Union Member States, organized by Africa CDC and hosted by the Egyptian United Procurement Authority (UPA) in Cairo. This collaboration aims to develop the first ever digital-to-biologics, end-to-end mRNA production platform, focusing on nucleic acid-based vaccines and therapeutics, including mRNA and saRNA vaccines for both human and animal health.&nbsp;
The platform, taking place in Egypt, will integrate DNA Script’s enzymatic DNA synthesis technologies with Quantoom’s Ntensify® mRNA synthesis and Ncapsulate® formulation technologies, combined with EVA Pharma’s vaccine development, top notch GMP sterile manufacturing expertise and commercialization capabilities. The collaboration addresses critical market needs, including rapid responses to infectious diseases outbreaks and routine immunizations.. The shared vision is to produce 100 million doses of RNA-based vaccines annually, fostering localization and strengthening regional autonomy in biopharmaceutical manufacturing. This collaboration will focus on developing a next generation, saRNA-based vaccines, targeting both human and animal health under the One Health approach to create a stronger defense against zoonotic diseases from the source.&nbsp;
This initiative will contribute to achieve Africa CDC’s target of 60% local vaccine production by 2040 and Egypt’s ambitious goal to manufacture 385 million vaccine doses annually by 2030, establishing itself as a global leader in vaccine production. It also supports public health resilience and food security across Africa and the Middle East.&nbsp;&nbsp;
“This moment will reshape African and global health security as we know it.” Said Dr. Riad Armanious, CEO of EVA Pharma, expressing his enthusiasm. “Our cross-continental collaboration will empower patients with next-generation, scalable, and versatile solutions that transform what once took years into a process achievable in weeks. This is not tomorrow’s promise, it is today’s reality: with an operational biologics manufacturing site producing 100 million vials and 1.5 billion doses of animal health vaccine already commercialized, we have the infrastructure to streamline vaccine production using groundbreaking mRNA technology and ensuring unparalleled safety.”
According to Marc Montserrat, CEO of DNA Script,&nbsp;&nbsp;“Our collaboration with EVA Pharma and Univercells-Quantoom to implement our proprietary enzymatic DNA synthesis technology directly supports the mission to accelerate vaccine development and delivery worldwide, and more broadly aligns with our vision to make biology programmable. By dramatically reducing the time needed to produce DNA templates, and by enabling the synthesis of longer and more complex DNA sequences, we're helping ensure that innovative vaccine technology can reach those at highest risk during emerging epidemics more rapidly than ever before.”&nbsp;
José Castillo, CEO of Quantoom Biosciences, added: “This collaboration showcases the transformative power of combining complementary expertise across borders. Together, we are not only advancing RNA technologies but also addressing global health inequities by making life-saving vaccines and therapeutics accessible to underserved populations.”&nbsp;
Hala Audi, CEO of Unizima, echoed this sentiment: “EVA Pharma is already showing the world the power of investing in the biopharma sector to create health and wealth in Africa and the Middle East. We are proud to support the tech transfer of some of the best technology for DNA and RNA manufacturing to Egypt, as the next chapter in their growth.”&nbsp;
This MoU reflects a strong commitment to advance global health equity and foster sustainable biopharma development. By combining their strengths, the partners aim to deliver versatile, scalable, and impactful solutions. These will shape the future of healthcare in Egypt and beyond, while contributing to economic resilience and regional pandemic preparedness and response.&nbsp;
&nbsp;
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;=ENDS=&nbsp;
About EVA Pharma&nbsp;
EVA Pharma is dedicated to improving access to affordable, high-quality medicines around the world, focusing on three core pillars: innovation, development and sustainable access. The company leverages cutting-edge technology at two research centers bringing first-of-its-kind capabilities to the Middle East and Africa including mRNA research and development from AI prediction to biologic products.&nbsp;
With a 5,000-strong team of professionals, EVA Pharma produces more than one million healthcare products a day at four state-of-the-art manufacturing facilities, which are internationally recognized for innovation, and have been approved by multiple regulatory agencies.&nbsp;
Guided by a relentless drive to ensure sustainable access to pressing yet unmet disease areas, the company’s product portfolio focuses on twelve therapeutic areas: Anti-infectives, metabolic health, bone, neuroscience, oncology, respiratory, gynecology, urology and andrology, pediatrics, ophthalmology, gastrointestinal tract, family medicine to meet both local and international demand.&nbsp;
EVA Pharma is one of the fastest-growing healthcare companies in the Middle East and Africa, with an extensive pan-African presence, while operating in more than 70 countries worldwide.&nbsp;
For more information, please visit: www.evapharma.com &amp; https://www.evapharma.com/newsroom or follow us on Facebook, LinkedIn &amp; Instagram
&nbsp;
About EVA Pharma’s mRNA Innovation Hub&nbsp;
EVA Pharma has notably focused on localizing innovation in recent years through investing in research infrastructure and financing. The company has established an in-house research and development footprint, including its mRNA Innovation Hub, which is fully equipped to handle the complete mRNA vaccine development lifecycle—from digital sequencing to final drug formulation. This includes antigen selection, protein engineering, mRNA construct design, process development, innovative formulation delivery systems, and analytical method development.&nbsp;
&nbsp;
About DNA Script&nbsp;
DNA Script is at the forefront of transforming biological research through advanced enzymatic DNA synthesis technology. We provide pioneering solutions for DNA production, including our cutting-edge SYNTAX® DNA printer and our enzymatic synthesis technology that enables the production of longer and more complex DNA sequences. Our innovations are driving progress across critical scientific domains, including mRNA vaccine development, cell and gene therapy, and broader biomolecular research. By offering researchers unprecedented capabilities to synthesize high-quality DNA sequences, we are accelerating discoveries that have the potential to revolutionize healthcare, biotechnology, and scientific understanding.&nbsp;
&nbsp;
About Quantoom Biosciences&nbsp;
Quantoom Biosciences is leading the revolution in mRNA- and saRNA-based vaccines and therapeutics by providing turnkey solutions for (sa)mRNA &amp; LNP manufacturing. Its cutting-edge Ntensify® technology enables the production and purification of mRNA through a fully integrated, scalable system that combines processes, equipment, reagent mixes, and disposables. This solution supports the entire spectrum of mRNA production, from R&amp;D to commercial manufacturing. Launched in 2023, Ntensify has already been widely adopted across multiple continents, showcasing its global appeal. Quantoom Biosciences is also developing the Ncapsulate® technology for mRNA-LNP formulation and purification, aiming to significantly increase the accessibility and affordability of mRNA-based drugs. Located in Belgium, Quantoom Biosciences thrives in a dynamic biotech ecosystem, driving innovation in mRNA production to make life-changing therapies available to everyone, everywhere. More info : www.quantoom.com&nbsp;
&nbsp;
About Unizima&nbsp;
Unizima is a trusted consultancy specialized in public and private partnerships for establishing bioproduction facilities and develop the workforce in emerging biotech ecosystems. As a partner to biopharma manufacturers, governments, and global health agencies, Unizima enables the sustainable production of biologics—including vaccines, monoclonal antibodies, and recombinant protein. From project inception to technology transfer and training, Unizima integrates all necessary elements to bring biomanufacturing initiatives to life. More info: www.unizima.com&nbsp;&nbsp; 
Contact details&nbsp;
EVA Pharma&nbsp;
Marina Mansour&nbsp;
Corporate communications professional&nbsp;
Marina.mansour@evapharma.com 
DNA Script
Rachel Macmaster, PhD
Director, Global Marketing
<span style="font-size: 12.0pt; line-height: 115%; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Aptos; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;">&nbsp;publicrelations@dnascript.com&nbsp;&nbsp;
&nbsp;
Quantoom Biosciences / Unizima&nbsp;
Jonathan Lecocq&nbsp;
MarCom Manager&nbsp;
j.lecocq@quantoom.com&nbsp;
+32 476 81 12 44&nbsp;
&nbsp;
Disclosure Statement&nbsp;&nbsp;
The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified using forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law. &nbsp;

thumbnail_WhatsApp Image 2025-02-05 at 10.06.15 2.jpeg

WhatsApp Image 2025-02-05 at 10.06.15 2.jpeg

Africa and Europe Join Forces to Revolutionize RNA-based Vaccines and Therapeutics Production: MoU Signed Between EVA Pharma, DNA Script, Quantoom Biosciences

Press Release

EVA Pharma Hosts a High-Level Delegation from Germany’s Federal Ministry for Economic Cooperation and Development (BMZ) and Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ)

2026-06-19

Top News

Press Release

2026-06-19

Press Release

2025-11-03

Press Release

2024-12-16

Top News

Press Release

EVA Pharma Hosts a High-Level Delegation from Germany’s Federal Ministry for Economic Cooperation and Development (BMZ) and Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ)

2026-06-19

© 2026 Eva Pharma All Rights Reserved - شركة ايفا فارما للادوية و المستلزمات الطبية